Summit Research Initiates Imperva At Buy

Summit Research initiated coverage on

with a Buy rating. The target price for Imperva is set to $75. Imperva shares have gained 171.59 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period. Imperva shares fell 0.15 percent to close at $67.00 on Thursday.